Author: Emilie Schuester 
, 
Estimated Reading Time: 4 min 
Excelya Key Takeaways from ESMO 2026
ESMO 2026 confirmed that oncology has entered a new era where innovation is increasingly driven by highly targeted, biomarker-guided, and immune-mediated therapies. While immune checkpoint inhibitors remain an important foundation, the congress highlighted the emergence of new therapeutic modalities capable of delivering clinically meaningful benefits across multiple tumor types.
The Main Therapeutic Mechanisms Driving Innovation
Antibody-Drug Conjugates (ADCs)
ADCs were one of the dominant themes of the congress, with positive results reported across several solid tumors. Studies such as ARTEMIS-011 with Risvutatug Rezetecan (osteosarcoma) and trials involving Arcotatug Tavatecan demonstrated the growing clinical impact of targeted cytotoxic delivery strategies. These data reinforce ADCs as one of the fastest-expanding classes in oncology drug development.
T-Cell Engagers and Bispecific Antibodies
T-cell redirecting therapies emerged as a major breakthrough area. The Phase III DeLLphi-304 study demonstrated a significant overall survival benefit with Tarlatamab in relapsed small-cell lung cancer, positioning T-cell engagers as a promising alternative to more complex cellular therapies.
Immunotherapy Combinations
The next wave of immunotherapy is increasingly based on combination strategies. Regimens combining anti-PD-L1 and anti-CTLA-4 agents, such as Durvalumab and Tremelimumab, continued to demonstrate encouraging results, particularly in hepatocellular carcinoma.
Precision Oncology
Targeted therapies remain central to oncology innovation. Significant advances were reported for KRAS- and HER2-driven cancers, notably with Divarasib in KRAS G12C-mutated NSCLC and Zanidatamab in HER2-positive gastroesophageal cancer. These results further validate molecular profiling as an essential component of clinical development.
Personalized mRNA Cancer Vaccines
One of the most anticipated breakthroughs of the congress was the presentation of Phase III results from INTerpath-001, demonstrating that the personalized mRNA neoantigen vaccine Intismeran Autogene (mRNA-4157/V940) combined with pembrolizumab reduced the risk of recurrence or death by 42% in high-risk melanoma. This represents the first Phase III validation of an individualized mRNA cancer vaccine and potentially the beginning of a new therapeutic platform in oncology.
Emerging Role of AI in Oncology Research
Artificial Intelligence was another recurring theme throughout the congress. While AI remains at an early stage for direct clinical decision-making, multiple studies demonstrated its value in clinical trial operations, including patient identification, biomarker prescreening, trial matching, data extraction from medical records, and multidisciplinary tumor board support. The growing integration of AI is expected to improve study efficiency and accelerate enrollment, particularly in biomarker-selected populations.
Real-World Evidence (RWE) Becomes a Strategic Asset
Beyond traditional randomized clinical trials, ESMO 2026 highlighted the increasing importance of Real-World Evidence (RWE). Investigators presented data demonstrating how real-world datasets can complement clinical trial results, support evidence generation in rare cancers, evaluate long-term outcomes, and better characterize treatment effectiveness in routine clinical practice. RWE is becoming an increasingly important component of regulatory, reimbursement, and clinical development strategies.
Together
Together, these takeaways highlight the growing role of targeted therapies, immune-mediated approaches and personalized cancer vaccines in oncology innovation, alongside AI-supported trial operations and real-world evidence in clinical development.
Looking Forward
Shaping the Future of Oncology
ESMO 2026 demonstrated that the future of oncology will be shaped by five major innovation pillars: ADCs, T-cell engagers and bispecific antibodies, immunotherapy combinations, precision medicine, and personalized mRNA cancer vaccines. These advances are increasingly supported by AI-enabled trial execution and the growing integration of real-world evidence, creating a more personalized, data-driven, and efficient oncology development landscape
Similar resources
